Stem cell research and the intellectual property derived from it, because of its potential to completely transform health care, demand an especially high level of consideration from business and patent prosecution perspectives. As with other revolutionary technologies, ordinary risks are amplified (e.g., litigation), and ordinarily irrelevant considerations may become important (e.g., heightened level of both domestic and foreign legislative risk). In the first part of this article, general strategies for patent prosecutors such as several prosecution considerations and methods for accelerating patent prosecution process are presented. In the second part, patent prosecution challenges of stem cell-related patents and possible solutions are discussed. In the final part, ethical and public policy issues particular to stem cell-related and other biotechnological inventions are summarized. (Journal of Biomolecular Screening 2007:769-774) 
INTRODUCTION
T HE UNITED STATES GRANTS PATENTS to "whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement," in addition to meeting disclosure, novelty, and nonobviousness requirements. 1 Biotechnology patents are different from other patents because they require highly specific facts to meet these statutory requirements. 2 To successfully and efficiently patent emerging biotechnological inventions (see Table 1 ), the general strategies of carefully balancing patent prosecution considerations and speeding up the patent prosecution process should be employed. Furthermore, specific patenting challenges unique to stem cell-related patents should be taken into account. Furthermore, ethical and public policy issues surmounting stem cells must be considered.
GENERAL PATENT STRATEGIES

Patent prosecution considerations
Assessment and analysis of a company's intellectual property inventory and its business objective. The starting point in intellectual property for new companies is an evaluation of the current state of intellectual property owned or licensed by the company. 3 Some relevant questions are the following: Is the purpose of this intellectual property to expand new products or protect existing ones? Which technologies form the core of the product line? Which inventions provide value more in the short term than the long term? Who are the important competitors, and which technologies will they need to continue to compete? Through answering these and related questions, patent applications may be categorized as "will use," "likely not to use," or "will not use." Based on these classifications, a sensible business plan for these technologies may be developed. 3 Building a patent portfolio quickly by acquiring or licensing patents/applications from universities or defunct companies. Many biotechnology companies build or strengthen their patent portfolios by either negotiating with universities for exclusive or nonexclusive licenses of their inventions or by acquiring patents from defunct companies. Until the Bayh-Dole Act in 1980, 4 "the federal government sponsored basic research and encouraged its widespread publication in the public domain without regard for potential commercial applications." 5 After this legislation was enacted, universities were able to transfer their patented technology to businesses. Universities benefit from the revenue generated from the licensed technology (e.g., Cohen-Boyer's recombinant DNA patent). 6 The business benefit is similarly clear 7 ; many small or start-up biotechnology firms rely on exclusive licensing rights to ensure access to high-risk capital and to promote investment in downstream development. 8 Due diligence on patent applications and extensive search for potential infringement. Conducting due diligence on patent applications and extensively searching for potential infringements on the issued patents are always important in serious patent prosecution. Diligent organization of a patent portfolio and vigilant surveillance of competitors' activity or other third party's potential patent infringement will provide protection to an invention and can be used to soften the hazard of litigation. 9 An extensive search for potential infringement on issued patents will help patent applicants decide whether to pursue patents for their inventions or to alter their invention to avoid infringement. A biotechnology-related patent is time-consuming and expensive. It requires an average of 3 years to complete and costs upwards of $15,000. Thus, prior to committing resources to developing a new product, potential infringement should be thoroughly investigated. 9 Blocking strategy. In addition to the defensive strategy of protecting a company's preexisting core technology, an offensive strategy may be useful. An intelligent offensive patent strategy may be used to block future competition, secure emerging standards, increase the company's valuation, and collect licensing royalties. This strategy may be carried out by patenting or purchasing patent rights related to an emerging standard or trend. As an example of this strategy, Microsoft patented the interface used in Apple's iPod; if the patent turned out to be valid and iPod was determined to infringe upon it, Microsoft would gain some iPod revenue for "inventing" the interface despite having nothing to do with manufacture or development of the product. Similarly, a company developing stem cell-related therapy for a specific purpose, such as cancer treatment, might face a challenge to keep stem cell lines fresh and usable. The company might predict a certain method and successfully prosecute a patent. If the prediction turns out to be true, the company can generate revenue in the future despite some ignorance of the manufacturing process or the other contributing causes of the problem.
Deriving and maximizing value from nonused and used patents. A patentee may intelligently elect not to license patented core-technological inventions to preserve an exclusive position in the market. 10 However, to maximize the value of a portfolio of patents, patentees may consider 1) licensing out patents that may not be used because the patents do not meet the company's business objective, 2) filing for infringement litigation against competitors to obtain monetary damages and exclusive positions in the marketplace, or 3) cross-licensing with competitors for necessary technology to gain market access. 3 Because a large number of stem cell patents have been issued, most companies will have to opt for cross-licensing agreements to remain competitive. As of May 22, 2007, 11,192 of the patents available for download at the US Patent and Trademark Office (USPTO) Web site made some mention of stem cells, many tangentially but virtually all in earnest and unrelated to plant matter. There were 276 issued patents that include the term in the title.
Speeding up the process of patent prosecution
Submitting a petition to make special. An excellent strategy to increase patent protection speed is to claim high priority within the USPTO. 11 An application can advance out of turn for examination or for further action if it is made special on the grounds of prospective manufacture, actual infringement, applicant's health and age, environmental quality, recombinant DNA-related invention, certain new applications, HIV/AIDS and cancer-related inventions, counterterrorism-related inventions, and applications relating to biotechnology filed by applicants who are small entities. Some of these categories legitimately apply to nearly all stem cell-related innovations, so petitions to make special should correspondingly be filed often on patents related to this technology.
Making narrow claims only. The USPTO requires a limited claim scope for biotechnological patents and usually restricts support for claims to working examples in the specification. As a result, broad patent claims are likely to be rejected if insufficient working examples are provided. 12 The Federal Circuit Court in Amgen v. Chugai held that §112 requires the scope of the claims to bear a reasonable correlation to the scope of enablement provided by specification to persons of ordinary skill in the art. 13 Thus, claiming all possible genetic sequences that have a particular protein-like activity by merely making a protein's generic DNA sequence is insufficient and invalid. The court in University of California v. Eli Lilly further ruled that a description of rat insulin cDNA is not a description of the broad classes of vertebrate or mammalian insulin cDNA. A written description of an invention involving a chemical genus, such as a description of a chemical species, requires a precise definition of the claimed subject matter sufficient to distinguish it from other materials. 14 Accordingly, narrow and specific claims are more likely to increase the speed of patent issuance. If desired, broader claims may then be sought in a continuing application. 15 These 3 core patents are owned by the Wisconsin Alumni Research Foundation (WARF) and cover most of US ES cell research and preclude others without license from using, selling, or conducting research on stem cells obtained from primates. The broad nature of patent originates from the fact that these patents cover the actual cell lines and the protocols for making them. In 2006, the Foundation for Taxpayer and Consumer Rights (FTCR) challenged the first 2 patents and raised the argument that Thomson's patent is merely a follow-up work of published research by Robert Williams, an Australian researcher, before 1995. Williams's work on developing a method for isolating mammalian stem cell was granted a patent in 1992. The FTCR's objection for the lack of novelty and nonobviousness is responded by the fact that human ES isolation is possible after substantial improvement in preexisting techniques. Under the current situation, it is necessary to define strategies for choosing narrow or broad claims in stem cell patent prosecution.
Discovery results in patent, and patent encourages further discoveries to surpass existing patented discoveries. Apart from Thomson's effort, several other researchers have discovered innovative ways to isolate ES. How much these new protocols are different from Thomson's protocol and how these are safe from infringement issues depend on the claims made and scientific terms buried in the core patents. A detailed knowledge of science behind complex stem cell research and legalities behind complicated patent laws is therefore necessary in drafting claims. Less than 2 years before Thomson's report on ES cells, Ian Wilmut used somatic cell nuclear transfer (SCNT) to generate Dolly, the first mammal cloned from the adult donor cell. This method could have paved ways to make ES cell lines. 16 Although Wilmut's patent claims nonhuman uses of SCNT for the production of animals, several techniques claimed in the patent can be used to produce ES cells in animals, including humans. Apart from the techniques used by Thomson or Wilmut, several new potential techniques have been reported to isolate ES, each of which is significantly novel but not quite out of the premises of the core patents. Some of these techniques include altered nuclear transfer (ANT), cell fusion, embryo biopsy, parthenogenesis, and improvements in SCNT.
In addition, there is a need to finely redefine the terms and definitions involved in stem cell research because biological development of a single cell into a multicellular adult animal is a gradual process, and it is hard to draw a line to demarcate one stage from another stage of development. Several influencing factors involved in stem cell isolation, such as site of origin, molecular signature, and spatial and temporal localization, can further increase present ambiguities in defining terms. Although the patents owned by WARF deal with ES cells, terms such as embryo and embryonic are not elucidated. The evolving redefinition of terms and new definitions in stem cell research could change the scope of claims and bring a new breadth in licensing.
In a recent development, on March 30, 2007, the USPTO acknowledged the objections put forward by the FTCR against WARF and issued a preliminary denial to WARF's patent claims. It is quite common to issue preliminary denial in the reexamination process, and it is important to note that in most cases, the USPTO upholds the original status or adds some modifications.
Bioinformatics-related software patent prosecution
Bioinformatics is the use of computational tools and databases in relation to genomic, proteomic, medical, and health data. 17 Stem cell therapies are complex because the environment in which the cells are placed influences the gene expression. Therefore, prosecution of stem cell patents will need a good understanding of the concerns unique to bioinformaticsrelated patents.
The USPTO created a special examination unit, Art Unit 1631, in December 1999, to review bioinformatics-related patent application. By May 22, 2007, a total of 1818 patents had already been issued by the USPTO for bioinformaticsrelated invention. 17 Most bioinformatics inventions involve applications of computer-implemented protocols or software in collecting, storing, processing, or analyzing biological data. The patentability and protectability of software inventions have been an intensely debated topic for decades. According to the US Court of Appeals for the Federal Circuit (CAFC) in In re Warmerdam 18 and In re Lowry, 19 claims to data structures per se do not constitute patentable subject matter pursuant to 35 USC §101. However, a machine (such as a computer) or a computer-readable medium (such as a CD-ROM or floppy disk) encoded with a data structure is patentable. These rulings are consistent with the USPTO's guideline for patentable subject matter in computer-related inventions: "when functional descriptive material is recorded on some computer-readable medium it becomes structurally and functionally interrelated to the medium and will be statutory in most cases since use of technology permits the function of the descriptive material to be realized." 20 Thus, a machine or software having a practical application in the technological arts is patentable. [20] [21] [22] Technical application could be identification of a drug target or prediction of a protein structure. For example, Affymetrix developed application software that enables researchers to perform gene expression, single-nucleotide polymorphism (SNP) mapping, and resequencing analysis, with integrated
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data management and scalable client-server configuration (http:// www.affymetrix.com/products/software/index.affx).
Patent prosecution in bioinformatics presents a certain degree of difficulty. First, the value of the therapeutic products is more lucrative than the tools (software) used to identify these products. Many bioinformatics companies have employed the tactic of "reaching through" claims by establishing mechanisms to claim profitable bioinformatics-derived therapeutic products rather than the tool used for their identification. However, because these patents are mostly related to screening methods that are upstream from the therapeutic product, 17 drafting the claims purely based on the tools may be insufficient. One solution is to limit the scope of the claim. Alternatively, if it can be shown that the claims are enabling to one of ordinary skill in the art, rejection for insufficiency of this type of claim may be overcome.
Another problem is the variety of business models being used in the industry. Some bioinformatics market participants may license access to databases, whereas others may sell software, systems, and test equipment or perform tests for clients. Because effective patent claims cover what is sold, patent prosecutors should anticipate such diverse business models and aim to block future competitors when drafting claims. 2 The interdisciplinary nature of bioinformatics-related patents also presents challenges both to the USPTO and patent prosecutors. The scarcity of judicial precedents and the difficulty of finding a patent drafter or examiner who is well versed in information technology, biology, and patent law increase the difficulty and effort of obtaining a bioinformatics patent. Furthermore, because the bioinformatics field develops quickly, the success of drafting patent applications should be based on a vision of the future progress of bioinformatics, in addition to the knowledge of patent law and business.
Genomics patent prosecution
Certain challenges exist for prosecuting genomics-related inventions to meet the utility requirement. These challenges apply equally to a subset of stem cell-related patent applications. According to the USPTO's new utility guidelines, 23 inventions must have well-established utility, such that a person of ordinary skill in the art would immediately appreciate why the invention is useful based on the characteristics of the invention. Moreover, the utility must be credible, substantial, and specific. For genomics-related patents, the utility of a specific DNA sequence is often unclear until further characterization of its function and activity. A sequence of DNA fragment without any indication of a function or specific asserted utility is not patentable. 9 For example, Incyte and similar genomics companies filed thousands of provisional patent applications with the USPTO for expressed sequence tags (ESTs), whose functions were unknown. Opponents of this tactic argue that patent rights should be reserved for uncovering the true biological function of a gene, not merely sequences of the gene fragments. 24 Similarly, discoveries about stem cells may not be obviously useful, although potential uses are plenty. The concern may be less than that in genomics because of the common perception of therapeutic utility based on stem cells.
Another tactic to meet the utility requirement is to conduct several functional assays. The inventor can submit a declaration on sequence behavior asserting that the invention is more likely than not to have the same function. The invention is still protected even if a new usage is discovered for the original claims. For example, Viagra was originally patented as a heart remedy. 24 This possibility may be particularly significant to stem cells because there are many poorly defined potential applications.
Some genomics-related claims are too general to meet the written description requirements. Under the guidelines for the written description, a patent specification must describe the claimed invention in sufficient detail that one skilled in the art could reasonably conclude that the inventor had possession of the claimed invention. 25 The federal district court in University of California v. Eli Lilly held that merely naming a type of known material, without any knowledge as to what that material consists of, is not a description of that material. 14 For example, a generic statement such as "vertebrate insulin cDNA" or "mammalian insulin cDNA" is not an adequately written description of the genes because it does not distinguish the claimed genes from others, except by function. A definition by function is not sufficient to define the genes because it is only an indication of what the gene does, rather than what they are. 26 In the case of stem cells, this consideration translates well: there are many researchers who claim a great stem cell therapy if only they could overcome some mechanistic hurdle. Patenting a new application of stem cells may require not only claiming the utility but also sufficient elucidation of how the stem cells would have to be adapted or a convincing explanation for why no adaptation is necessary.
ETHICAL ISSUES AND PUBLIC POLICY
Recently, the patentability of new biotechnological inventions related to human embryonic stem cells, human cloning, and human/nonhuman chimeras has raised not only technical challenges to patent prosecution but also moral and ethical concerns. The USPTO determines patentable subject matter under 35 USC §101 on a case-by-case basis following tests set forth in Diamond v. Chakrabarty. 27 For example, 1 such test says that an artificial manufacture or composition of matter is patentable. 28 The USPTO considers purified and isolated stem cells and human cloning-related inventions patentable subject matter and rarely rejects applications based on public policy and morality grounds, as long as the criteria of novelty, utility, and nonobviousness are met. 29 For example, the USPTO has issued several patents on cloning methods specifically related to nonhuman animals, such as patents granted to Geron-Biomed and the University of Massachusetts at Amherst. 30 However, the USPTO did not grant a patent on the claimed human/nonhuman chimera based on the argument that granting patents on people would violate the 13th Amendment to the Constitution abolishing slavery, claiming that neither the USPTO nor Congress has ever defined human. Furthermore, in a media advisory issue in 1998, relying on the decision from Tol-O-Matic Inc. v. Proma Produckt-und Marketing Gesellschaft, the USPTO stated that the utility requirement of §101 excludes inventions deemed to be "injurious to the well being, good policy, or good morals of society." 31, 32 These conflicting decisions from the USPTO question the ability of US patent laws as a means of regulation. 30 The patent system lacks the expertise and resources to engage in regulating outside the USPTO's expertise, and the USPTO is not really authorized to make regulatory changes due to societal concerns for all of its applications. Also, a refusal to grant a patent for such controversial biotechnological inventions does not prevent the application. 30 The patent right is a right to exclude others from making, using, and selling the invention, not a right to do something. 31, 32 Thus, by not granting a patent, the USPTO may instead enable anyone to practice the disrupted technology. Patent law only enables the USPTO to either grant or not grant a patent. The USPTO does not have a wide range of regulation options. 30 Although the USPTO may grant or reject a controversial biotechnological invention, it does not get to regulate all of industry through patents.
However, the federal and state legislatures of the United States and governing bodies of foreign governments have some measure of power over industrial applications. Most of these units have exercised their power on the subject of stem cells, even before a major health application has been deployed. Legislative risk is likely the most significant risk to ventures dependent on stem cell therapies for revenue. Stem cell technologists were set back by a freeze on federal funding for new stem cell lines since 2001. In 2004, California stem cell technologists were granted a new lease on life by a voter initiative (Proposition 71). Various interest groups throughout the globe have strong feelings about technologies pertaining to embryonic stem cells, and these feelings continue to find expression in law. Mitigating these risks involves a careful combination of campaign contributions (unfamiliar to big pharmaceutical companies and other large industries), public awareness campaigns touting the benefits of stem cell therapies, and vigorous lobbying efforts.
CONCLUSIONS
Patenting new biotechnological inventions provides a constant challenge. In addition to its fast growth and increasingly interdisciplinary nature, both patent prosecutors and the USPTO face the ethical and public policy issues of patenting human cell-related inventions. Even though patents are only a part of an intellectual property strategy, effective and efficient patent strategies are essential to provide incentives to advance biotechnology research and growth of the industry.
